Ophthalmic diseases continue to place increasing strain on healthcare systems across the Asia-Pacific (APAC) region, driven by ageing populations and a rising burden of chronic vision-related conditions. Against this backdrop, the ophthalmic devices market in APAC is projected to grow at a 2.5% compound annual growth rate (CAGR) between 2026 and 2036, forecasts GlobalData, a leading intelligence and productivity platform.

GlobalData’s research reveals that APAC accounted for approximately 30% of the global ophthalmic devices market in 2025, owing to better access to eye care, improved healthcare infrastructure and investment, higher surgical volumes, and wider use of modern diagnostic and surgical technologies in the region.

Pandorum Technologies has recently collaborated with Nucelion Therapeutics, a contract research, development, and manufacturing organization (CRDMO) and a wholly owned subsidiary of India’s Bharat Biotech. This partnership aims to expand the manufacturing capacity for exosome-based therapies that target ocular diseases across APAC. It will help meet the growing regional demand for next-generation biologic treatments.

Divya Soni, Medical Devices Analyst at GlobalData, comments: “As biologics and regenerative therapies progress toward wider clinical use, the availability of scalable and compliant manufacturing infrastructure becomes increasingly important. Strengthening regional production capabilities in APAC could help reduce the development bottlenecks while improving access to advanced ocular therapies. The move also underscores India’s emerging role in biologic therapy development and manufacturing.”

The initial focus of the collaboration is on serious ocular conditions, including ocular surface injuries and inflammatory corneal diseases such as Stevens–Johnson syndrome and neurotrophic keratitis, which are often associated with chronic pain and significant vision loss. Beyond ophthalmology, Pandorum has also highlighted the potential of its exosome platform for applications in other inflammation-driven and degenerative conditions.

Soni concludes: “Developments such as this highlight the APAC region’s growing role in advanced biologics and regenerative medicine manufacturing. As exosome-based therapies gain traction globally, expanding scalable and compliant production capacity in the region could support improved access to next-generation ocular treatments and reinforce APAC’s position within the global advanced therapeutics supply chain.”